A paper presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend showed that histologic subtypes of metastatic renal cell carcinoma (RCC) differ in the location of their metastases. For example, lung, adrenal, brain, and pancreatic metastases occur more frequently with clear cell RCC than with papillary RCC or chromophobe […]
A recent retrospective study looked at the data from 49 patients with metastatic papillary renal cell carcinoma (RCC) who were taking targeted therapy (VEGF-TKIs). The study showed that patients on targeted therapy and with bone metastases from papillary RCC have worse progression-free survival and overall survival than patients without bone metastasis. Patients with papillary RCC […]
Results from a phase II study of bevacizumab and erlotinib in people with advanced hereditary leiomyomatosis and papillary renal cell cancer (HLRCC) or sporadic papillary RCC were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. This study included 83 patients with papillary RCC. Half of the patients […]
In a study presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, the tyrosine kinase inhibitor (TKI) savolitinib was shown to be more effective and safer than sunitinib as a treatment for people with papillary renal cell carcinoma (RCC). Papillary renal cell carcinoma accounts for approximately 15% of all RCC, making […]
In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC). The study enrolled 60 patients, 42 of which had non-clear cell RCC […]
Nivolumab alone and in combination with ipilimumab is used for the treatment of patients with metastatic renal cell carcinoma (RCC) in the second- and first-line, respectively. However, since patients with non-clear cell RCC are excluded from clinical trials, there is limited data on the effectiveness of nivolumab for the treatment of these patients. In a […]
The majority of renal cell carcinomas (RCCs) are a subtype called clear cell RCC. Most drugs have been developed to treat this subtype of RCC, leaving people with other metastatic RCC subtypes with an unmet need for an effective treatment in the first-line. Papillary RCC (pRCC) represents 10-15% of renal cell carcinomas, and is not an insignificant subtype. […]
Overall survival results from a study with a combination of savolitinib and durvalumab for papillary renal cell carcinoma (RCC) patients were reported at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held in San Francisco last weekend. Metastatic papillary RCC has poor outcomes and there is need for new treatments. In this phase 1/2 study (CALYPSO), a […]
Papillary renal cell carcinoma (PRCC) is a rare subtype of renal cell carcinoma (RCC), accounting for 10%-15% of all cases of RCC. There are two types of papillary RCC; type 1 and type 2. Currently, there is an unmet need for an effective first-line treatment for metastatic PRCC. A recent phase 2 study, published in […]
In a recent analysis of a large database, researchers compared baseline clinical/pathological characteristics and survival outcomes of localised type 1 papillary renal cell carcinoma (pRCC) and type 2 pRCC patients. This study, the largest study of localised pRCC published to date, showed that type 2 pRCC patients were more likely to be diagnosed with higher […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
